secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001171843-24-002612
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q1 net loss $34.9M; Phase 2a HERALD study commenced, topline expected Q4 2024
--------------------------------------------------------------------------------

- Net loss of $34.9M ($0.22 per share) vs $23.0M ($0.53) in Q1 2023; increase due to non-cash warrant liability charge.
- Cash and investments $112.7M, down from $135.7M at Dec 2023; runway through end of 2025.
- Phase 2a HERALD study (ALG-055009 for MASH) started dosing April 2024; topline data expected Q4 2024.
- Received additional $1.3M NIH grant for pan-coronavirus protease inhibitor ALG-097558; Phase 2 enabling activities underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184324002612/0001171843-24-002612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184324002612/f8k_050724.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer